Related coverage linked through entity extraction aliases.
Mar 08, 2026
New research shows genomic profiling can detect aggressive prostate cancer not identified at biopsy, while a separate study reveals PTGES3 as a potential therapeutic target for treatment-resistant disease.
Mar 08, 2026
A six-year study in Liberia found that 11% of patients admitted with fever had undiagnosed Lassa fever, with mortality exceeding 20% in some settings and children comprising 43% of confirmed cases.
Mar 08, 2026
Scientists at three institutions have developed distinct nanoparticle-based drug delivery systems designed to target cancer tumors more precisely while reducing side effects, with approaches ranging from DNA nanomachines to transformable nanofibers.
Mar 07, 2026
Dr. Vinay Prasad, director of the FDA's Center for Biologics Evaluation and Research, will depart the agency by the end of April to return to an academic role at the University of California San Francisco.
Mar 07, 2026
Moffitt Cancer Center researchers published findings on plant-based diets and cancer risk, identified spatial tumor-immune patterns predicting immunotherapy response, and hosted a summit on engineering-driven cancer research innovations.
Mar 06, 2026
New research reveals how GLP-1 receptor agonists promote pancreatic health through gene expression changes and interact bidirectionally with gut microbiome, while real-world users report unexpected lifestyle changes alongside weight loss.
Mar 05, 2026
New research reveals that different KRAS mutation types create distinct tumor ecosystems with varying immune responses, potentially enabling personalized treatment strategies combining mutation-specific inhibitors with immunotherapy.
Mar 01, 2026
A large long-term NIH-funded trial found that older adults who practiced visual speed training were 25% less likely to develop Alzheimer's disease or other dementias even 20 years later, marking the first randomized clinical trial to assess such long-term links.
Mar 01, 2026
Inovio Pharmaceuticals trades as a speculative micro-cap biotech on NASDAQ, with DNA medicine candidates in oncology and infectious disease facing binary clinical risks and ongoing capital needs.
Feb 28, 2026
Three interconnected life sciences infrastructure markets are experiencing significant growth driven by precision medicine adoption, increasing clinical trial activity, and advances in genomic diagnostics through 2035.
Feb 23, 2026
A multicenter study of over 500 children found no differences in neurodevelopmental outcomes between offspring of mothers who received mRNA COVID-19 vaccines during pregnancy and those who did not.
Feb 18, 2026
A House Energy and Commerce subcommittee hearing on Feb. 11 revealed sharp partisan divisions over drug pricing solutions, with Republicans focusing on PBM reform and supply chain transparency while Democrats defended existing price negotiation policies and warned of threats from research funding cuts.
Feb 26, 2026
New research from Michigan State University reveals that differences in hormone-regulated monocytes explain why women experience longer-lasting chronic pain than men, with males producing more IL-10 to shut down pain signals.
Feb 26, 2026
The University of Colorado Anschutz School of Medicine rose to No. 21 nationally with nearly $314 million in NIH funding, while Colorado School of Public Health climbed to No. 17 with over $22 million. Wayne State University School of Medicine ranked 73rd with $61.6 million.
Feb 25, 2026
The FDA approved acalabrutinib combined with venetoclax for chronic lymphocytic leukemia and small lymphocytic leukemia based on phase III trial results. Separately, Yale researchers identified CD25 protein complex as a new drug target for aggressive leukemias.
Feb 25, 2026
New research addresses CAR T-cell therapy safety through a venetoclax-controlled on-off switch and a prospective study identifying neurotoxicity risk markers in pediatric patients with acute lymphoblastic leukemia.
Feb 25, 2026
The CDC's vaccine advisory committee meeting scheduled for February 25-27 has been canceled and rescheduled for March 18-19, as medical groups challenge the panel's composition and policies under Health Secretary Robert F. Kennedy Jr.
Feb 24, 2026
The FDA reversed its decision to reject Moderna's mRNA influenza vaccine application, accepting it for review one week after an initial refusal-to-file that reportedly involved senior leaders overruling staff advice.
Feb 24, 2026
Ralph Abraham resigned as CDC principal deputy director after less than two months, leaving the agency's top two positions vacant. The departure is part of broader HHS leadership changes under Secretary Robert F. Kennedy Jr.
Feb 19, 2026
Zsofia K. Stadler, MD, has been appointed as the next Editor-in-Chief of JCO Precision Oncology, effective July 1, 2026. She is an Attending Physician and Clinic Director at Memorial Sloan Kettering Cancer Center.
